Research Article| Volume 32, ISSUE 2, P293-299, February 2010

Download started.


Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit

      This paper is only available as a PDF. To read, Please Download here.


      Objective: This study evaluated the survival benefit of US community-acquired pneumonia (CAP) practice guidelines in the intensive care unit (ICU) setting.
      Methods: We conducted a retrospective cohort study of adult patients with CAP who were admitted to 5 community hospital ICUs between November 1, 1999, and April 30, 2000. The guidelines for antibiotic prescriptions were the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. Guideline-concordant antimicrobial therapy was defined as a β-lactam plus fluoroquinolone or macrolide, antipseudomonal β-lactam plus fluoroquinolone, or antipseudomonal β-lactam plus aminoglycoside plus fluoroquinolone or macrolide. Patients with a documented β-lactam allergy were considered to have received guideline-concordant therapy if they received a fluoroquinolone with or without clindamycin, or aztreonam plus fluoroquinolone with or without aminoglycoside. All other antibiotic regimens were considered to be guideline discordant. Time to clinical stability, time to oral antibiotics, length of hospital stay, and in-hospital mortality were evaluated with regression models that included the outcome as the dependent variable, guidelineconcordant antibiotic therapy as the independent variable, and the Pneumonia Severity Index (PSI) score and facility as covariates.
      Results: The median age of the 129 patients included in the study was 71 years (interquartile range, 60–79 years). Sixty-two of 129 patients (48%) were male. Comorbidities included liver dysfunction (7 patients [5%]), heart failure (62 [48%]), renal dysfunction (39 [30%]), cerebrovascular disease (21 [16%]), and cancer (14 [11%]). The median (25th–75th percentile) PSI score was 119 (98–142), and overall mortality was 19% (25 patients). Patient demographics were similar between groups. Fifty-three patients (41%) received guideline-endorsed therapies. Guideline-discordant therapy was associated with an increase in inpatient mortality (25% vs 11%; odds ratio = 2.99 [95% CI, 1.08–9.54]). Receipt of guideline-concordant antibiotics was not associated with reductions in time to clinical stability, time to oral antibiotics, or length of hospital stay when patients who died were excluded from the analysis.
      Conclusion: Guideline-concordant empiric antibiotic therapy was associated with improved survival among these patients with CAP who were admitted to 5 ICUs.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • DeFrances CJ
        • Lucas CA
        • Buie VC
        • Golosinskiy A
        2006 National Hospital Discharge Survey. National Center for Health Statistics, Hyattsville, Md2008 (National Health Statistics Report no 5.)
        • Kung HC
        • Hoyert DL
        • Xu JQ
        • Murphy SL
        Deaths: Final Data for 2005. vol. 56. National Center for Health Statistics, Hyattsville, Md2008 (National Vital Statistics Reports, no. 10.)
        • Angus DC
        • Marrie TJ
        • Obrosky DS
        • et al.
        Severe community-acquired pneumonia: Use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria.
        Am J Respir Crit Care Med. 2002; 166: 717-723
        • Houck PM
        • Bratzler DW
        • Nsa W
        • et al.
        Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
        Arch Intern Med. 2004; 164: 637-644
        • Gleason PP
        • Meehan TP
        • Fine JM
        • et al.
        Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
        Arch Intern Med. 1999; 159: 2562-2572
        • Kahn KL
        • Rogers WH
        • Rubenstein LV
        • et al.
        Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system.
        JAMA. 1990; 264: 1969-1973
        • Mandell LA
        • Wunderink RG
        • Anzueto A
        • et al.
        • Infectious Diseases Society of America
        • American Thoracic Society
        Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.
        Clin Infect Dis. 2007; 44: S27-S72
        • Bartlett JG
        • Breiman RF
        • Mandell LA
        • File Jr, TM
        • Infectious Diseases Society of America
        Community-acquired pneumonia in adults: Guidelines for management.
        Clin Infect Dis. 1998; 26: 811-838
        • Bartlett JG
        • Dowell SF
        • Mandell LA
        • et al.
        • Infectious Diseases Society of America
        Practice guidelines for the management of community-acquired pneumonia in adults.
        Clin Infect Dis. 2000; 31: 347-382
        • Benenson R
        • Magalski A
        • Cavanaugh S
        • Williams E
        Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality.
        Acad Emerg Med. 1999; 6: 1243-1248
        • Capelastegui A
        • Espana PP
        • Quintana JM
        • et al.
        Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: A controlled beforeand-after design study.
        Clin Infect Dis. 2004; 39: 955-963
        • Dean NC
        • Silver MP
        • Bateman KA
        • et al.
        Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia.
        Am J Med. 2001; 110: 451-457
        • Fine MJ
        • Stone RA
        • Lave JR
        • et al.
        Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: A randomized controlled trial.
        Am J Med. 2003; 115: 343-351
        • Marrie TJ
        • Lau CY
        • Wheeler SL
        • et al.
        • CAPITAL Study Investigators
        A controlled trial of a critical pathway for treatment of communityacquired pneumonia. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
        JAMA. 2000; 283: 749-755
        • Marrie TJ
        • Wu L
        Factors influencing in-hospital mortality in community-acquired pneumonia: A prospective study of patients not initially admitted to the ICU.
        Chest. 2005; 127: 1260-1270
        • Menéndez R
        • Ferrando D
        • Vallés JM
        • Vallterra J
        Influence of deviation from guidelines on the outcome of community-acquired pneumonia.
        Chest. 2002; 122: 612-617
        • Mortensen EM
        • Restrepo M
        • Anzueto A
        • Pugh J
        Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia.
        Am J Med. 2004; 117: 726-731
        • Bodí M
        • Rodríguez A
        • Solé-Violán J
        • et al.
        • Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators
        Antibiotic prescription for community- acquired pneumonia in the intensive care unit: Impact of adherence to Infectious Diseases Society of America guidelines on survival.
        Clin Infect Dis. 2005; 41: 1709-1716
        • Frei CR
        • Restrepo MI
        • Mortensen EM
        • Burgess DS
        Impact of guidelineconcordant empiric antibiotic therapy in community-acquired pneumonia.
        Am J Med. 2006; 119: 865-871
        • Fine MJ
        • Auble TE
        • Yealy DM
        • et al.
        A prediction rule to identify low-risk patients with community-acquired pneumonia.
        N EnglJ Med. 1997; 336: 243-250
        • Halm EA
        • Fine MJ
        • Marrie TJ
        • et al.
        Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines.
        JAMA. 1998; 279: 1452-1457
        • Menendez R
        • Torres A
        • Rodriguez de Castro F
        • et al.
        Reaching stability in community-acquired pneumonia: The effects of the severity of disease, treatment, and the characteristics of patients.
        Clin Infect Dis. 2004; 39: 1783-1790